Salute e Benessere

Notice to the Annual General Meeting of Orion Corporation

ORION CORPORATION STOCK EXCHANGE RELEASE / NOTICE TO GENERAL MEETING13 FEBRUARY 2024 at 12:15 EET Notice to the Annual General Meeting of Orion Corporation Notice is given to the shareholders of Orion Corporation of the Annual General Meeting to be held on Wednesday 20 March 2024 at 2:00 p.m. Finnish time at Messukeskus Siipi conference centre at the address Rautatieläisenkatu 3, Helsinki, Finland. The reception of attendees who have registered for the meeting and the distribution of...
Nasdaq GlobeNewswire
13/02/2024

Orion Group Financial Statement Release January–December 2023

ORION CORPORATIONFINANCIAL STATEMENT RELEASE 1-12/2023 13 FEBRUARY 2024 at 12:00 EETOrion Group Financial Statement Release January–December 2023Net sales totalled EUR 1,189.7 (January–December 2022: 1,340.6) million Operating profit was EUR 274.9 (439.6) millionBasic earnings per share were EUR 1.54 (2.49)Cash flow from operating activities per share was EUR 0.85 (3.09)Refined strategy and new financial targets for 2024–2028 The Board of Directors proposes a...
Nasdaq GlobeNewswire
13/02/2024

DelSiTech and Tolmar Announce Global License and Development Agreement

Under the terms of the license agreement, DelSiTech will be eligible to receive an upfront payment, development and commercial milestone payments, and royalties on net sales of licensed products. No amounts have been disclosed. Under the terms of the license agreement, DelSiTech will be eligible to receive an upfront payment, development and commercial milestone payments, and royalties on net sales of licensed products. No amounts have been disclosed. "We are thrilled to expand our...
PR Newswire
13/02/2024

Curasight resolves on a rights issue of up to DKK 51.2 million to accelerate its…

Summary of the Rights Issue Summary of the Rights Issue Reasons for the Rights Issue Curasight focuses on addressing the need for improved diagnosis and treatment of several cancer indications and has developed a highly specific PET imaging ligand, uTRACE (radioactive tracer) and uTREAT - both targeting the uPAR receptor. uPAR is expressed in many types of human cancers and the expression levels of uPAR have been shown to be strongly associated with metastatic disease, i.e. cancer...
PR Newswire
13/02/2024

Curasight announces acceleration of therapeutic strategy to strengthen position…

The Phase I/IIa basket trial is part of Curasight's strategy to be a leader in the field of theranostics within radiopharmaceuticals and diagnostics, combining improved diagnosis with more targeted, gentler and efficient treatment of cancers. The Phase I/IIa basket trial is part of Curasight's strategy to be a leader in the field of theranostics within radiopharmaceuticals and diagnostics, combining improved diagnosis with more targeted, gentler and efficient treatment of cancers. The new...
PR Newswire
13/02/2024

Implantica announces first RefluxStop™ public tender win, paving the way for…

Dr. Gabriele Pozzo says, "The RefluxStop procedure represents a new frontier in the surgical treatment of GERD. I'm so proud of our team at Ospedale Santa Croce of Moncalieri and how we came together to bring this innovative solution to our GERD patients." Dr.Gabriele Pozzosays, "The RefluxStop procedure represents a new frontier in the surgical treatment of GERD. I'm so proud of our team at Ospedale Santa Croce of Moncalieri and how we came together to bring this innovative…
PR Newswire
13/02/2024

Navamedic ASA: Invitation to 2023 4th quarter presentation

About Navamedic: About Navamedic: Navamedic ASA is a full-service provider of high-quality healthcare products to hospitals and pharmacies. Navamedic meets the specific medical needs of patients and consumers by leveraging its highly scalable market access platform, leading category competence and local knowledge. Navamedic is present in all the Nordic countries, the Baltics and Benelux, with sales representation in the UK andGreece. Navamedic is headquartered inOslo, Norway, and...
PR Newswire
13/02/2024

Innocan Provides Corporate Update & Preliminary Q4 and Fiscal Year 2023…

Technological Edge: Innocan's product development is centered around its proprietary CBD-loaded liposome platform technology ("LPT"), a testament to its commitment to innovation. This technology is designed for both human and animal applications, offering a new paradigm in treatment efficacy and safety. Additionally, Innocan's consumer wellness portfolio, featuring topicals and cosmetics, underscores its dedication to health and wellness, catering to the growing consumer demand for…
PR Newswire
13/02/2024

PanTera signs agreement with Bayer for the supply of actinium-225

Agreement demonstrates PanTera's unique ability to support the radionuclide therapeutics industry in bringing new cancer treatments to patients Mol, Belgium, February 13, 2023:PanTera, the Belgian joint venture created by IBA and SCK CEN to secure large-scale production of alpha-emitting radioisotopes, today announces the signing of a capacity reservation agreement with Bayer for the supply of actinium-225 ( 225 Ac) starting in the second half of 2024.This first agreement with a major...
Nasdaq GlobeNewswire
13/02/2024

Basilea reports strong 2023 full-year results with profitability significantly…

Increased Cresemba ®and Zevtera ® -related revenue of CHF 150.3 million (+22.9% year-on-year) at upper end of guidanceOperating profit of CHF 19.2 million and net profit of CHF 10.5 million, significantly above guidanceAddition of three new anti-infective assets to clinical portfolio, including phase-3-ready antifungal fosmanogepixStrong cash and restricted cash position of CHF 64.3 million, after fully absorbing investments into portfolio expansion and accelerated debt...
Nasdaq GlobeNewswire
13/02/2024

Half year reported NPATA US$2 billion¹,² Up 13% at constant currency³

MELBOURNE, Australia, Feb. 13, 2024 /PRNewswire/ -- CSL Limited (ASX:CSL; USOTC:CSLLY) today announces a reported net profit after tax of $1.90 billion1 for the 6 months ended 31 December 2023, up 20% on a constant currency basis3. Underlying profit (NPATA) was $2.02 billion1,2, up 13% on a constant currency basis to $2.06 billion1,2,3. MELBOURNE, Australia,Feb. 13, 2024/PRNewswire/ -- CSL Limited (ASX:CSL; USOTC:CSLLY) today announces a reported net profit after tax of$1.90 billion1...
PR Newswire
13/02/2024

Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the…

Friedreich's ataxia is a rare, genetic, life-shortening, debilitating, and neurodegenerative disorderTreatment with SKYCLARYS improved patient function compared to placeboBiogen is leveraging its expertise and capabilities in rare disease to bring this groundbreaking treatment to patientsCAMBRIDGE, Mass., Feb.12, 2024(GLOBE NEWSWIRE) -- BiogenInc. (Nasdaq: BIIB) announced the European Commission (EC) has authorized SKYCLARYS ®(omaveloxolone) for the treatment of Friedreich's...
Nasdaq GlobeNewswire
12/02/2024

Medical Tourism Patient Survey 2024 Shares Deep Insights into Barriers to…

The Medical Tourism Patient Survey reveals what underpins patients' healthcare behavior globally – trust. Almost all respondents who travelled for medical treatment (97.2%) considered trust to be one of the most critical pull factors. For patients and health consumers, trust comprises transparency, clear communication about treatment costs and other charges, communication about their treatment, credentials of healthcare professionals involved in their care, and a concrete medical plan when…
PR Newswire
12/02/2024

BioVaxys Acquires All Intellectual Property, Immunotherapeutics Platform…

Key transaction elements include a USD$750,000 upfront cash payment, various clinical development and regulatory milestone payments, a 15% share in license revenues, and a 6% gross sales royalty on product sales (such future gross sales royalties cancellable and extinguishable upon a one-time payment of USD$25,000,000 in cash) and shares of BioVaxys common stock with a deemed value of US$250,000, calculated at a price per share equal to the volume-weighted average price of the common shares…
PR Newswire
12/02/2024

dsm-firmenich completes voluntary cash offer for DSM shares

The holders of Shares who have sold their Shares through the Voluntary Tender Offer, will receive the offer price of €96.00 per Share on February 13, 2024, free from withholding or dividend tax. The total consideration payable by the Company under the Voluntary Tender Offer amounts to EUR 399,675,552. The holders of Shares who have sold their Shares through the Voluntary Tender Offer, will receive the offer price of€96.00per Share onFebruary 13, 2024, free from withholding or dividend...
PR Newswire
12/02/2024

EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as…

Disclosure of Share Capital and Voting Rights Outstandingas of January 31, 2024(Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des Marchés Financiers)Charenton-le-Pont, France (February 12, 2024 - 6:00 pm)– As of January 31, 2024, shares and voting rights outstanding of EssilorLuxottica, the global leader in the design, manufacture and distribution of ophthalmic lenses, frames and sunglasses,...
Nasdaq GlobeNewswire
12/02/2024

Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 12 February 2024– On 6 February 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2023. Under…
Nasdaq GlobeNewswire
12/02/2024

Transfection Technologies Market Worth $1.8 Billion | MarketsandMarkets™

Browse in-depth TOC on "Transfection Technologies Market" Browse in-depth TOC on "Transfection Technologies Market" 517 - Tables 48 - Figures 399 - Pages Transfection Technologies Market Scope: The kits & reagents segment accounted for the largest share by product type in the transfection technologies market in 2022. By product type, the transfection technologies market has been further categorized kits & reagents and equipment. Kits & reagents...
PR Newswire
12/02/2024

CeraVe Collaborates with Michael Cera and TikTok Stars on First-of-its-Kind…

For weeks, Michael Cera has been front and center in the news and across social media promoting his 'namesake' brand, CeraVe. Cera went toe-to-toe with dermatologists and even revealed his very own Michael CeraVe commercial. But the truth came out in a revealing ad, where Cera's bizarre campaign was debunked by a boardroom of CeraVe dermatologists, who reminded him that CeraVe is and always has been developed with dermatologists since 2005. In fact, the "Ve" stands for MVE Technology…
PR Newswire
12/02/2024

Frost & Sullivan Recognizes Innovaccer for Enabling Value-Based Care with Its AI…

The Innovaccer data platform establishes interoperability between healthcare IT systems, including legacy and mission-critical systems, to create a unified, longitudinal patient record. The platform also aggregates and cleans data from multiple sources, hydrates it to enable use in any application, activates it to integrate into workflows, and harmonizes it across relevant systems and care settings, ensuring it is synchronized. TheInnovaccer data platform establishes interoperability...
PR Newswire
12/02/2024

VST BIO Announces Groundbreaking Data from Non-Human Primate Study Evaluating…

Dr. Federico Corti, from the Cardiovascular Research Center of Yale University, presented data which showed that a single bolus of humanized anti-Syndecan 2 antibody (VST-002), administered either 3 hours or 6 hours after ischemia led to ~60% reduction of stroke damage as visualized by magnetic resonance imaging, with all measures being statistically significant over control animals. Histological analysis at 72 hours post-stroke confirmed a significant reduction of edema and area of necrosis in…
PR Newswire
12/02/2024

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives…

Bagsværd, Denmark, 12 February 2024— This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company's board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk...
Nasdaq GlobeNewswire
12/02/2024

PCI Biotech: Invitation to second half interim 2023 results presentation

The presentation will be held as a live webcast and can be accessed through www.pcibiotech.com. The presentation will be held in Norwegian. There will be a Q&A session at the end of the presentation and it will be possible to post written questions through the webcast console.The interim report and presentation will be made available on www.newsweb.no and on the company's webpage, www.pcibiotech.com, from 07.00am CET the same day.For further information, please contact: Ronny...
Nasdaq GlobeNewswire
12/02/2024

Qatar Airways and gategroup launch new partnership to Elevate Inflight Dining

NEWS PROVIDED BYgategroupFebruary 12, 2024, 09:00 AM CET Qatar Airways and gategroup launch new partnership to elevate inflight dining The airline with gategroup on board will set a new benchmark in inflight dining experience, quality, sustainability and healthy eating GLATTBRUG, Switzerland. February 12, 2024: Qatar Airways and gategroup today announced a new catering partnership to elevate inflight dining, structured through a Business Management Agreement that will see...
Nasdaq GlobeNewswire
12/02/2024
Altri  Comunicati